Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Atossa Therapeutics. The associated price target remains the same with $7.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on Atossa Therapeutics’ strategic advancements in their clinical development program for Z-endoxifen, particularly in the breast cancer treatment paradigm. The completion of a Type C meeting with the FDA has provided Atossa with valuable insights into clinical trial design and potential expedited regulatory pathways, which are expected to streamline the development process and shorten regulatory timelines. This positions Atossa favorably to implement multiple development tracks, including a Phase 2 neoadjuvant trial and a dose-ranging study for metastatic breast cancer, with an IND already submitted.
Additionally, Atossa’s decision to amend the design of the Phase 2 EVANGELINE trial is seen as a strategic move to accelerate data readouts while conserving resources. By reducing the patient count and focusing on objective endpoints, Atossa aims to extend its cash runway and prioritize NDA-enabling work for breast cancer risk reduction. These efforts, combined with the favorable safety and tolerability profile demonstrated by Z-endoxifen in previous studies, contribute to the positive outlook and Buy rating given by Emily Bodnar.
Bodnar covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, AnaptysBio, and Olema Pharmaceuticals. According to TipRanks, Bodnar has an average return of 7.9% and a 34.70% success rate on recommended stocks.